title: A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children.
abstract: Molluscum contagiosum is a common viral disease of childhood presenting as small, firm, dome-shaped umbilicated papules. Although benign and generally self-limited, this condition is contagious and can lead to complications such as inflammation, pruritus, dermatitis, bacterial superinfection, and scars. No consensus has been established concerning the management of this condition. We conducted a prospective randomized study comparing four common treatments for molluscum contagiosum in 124 children aged 1 to 18 years. One group was treated with curettage, a second with cantharidin, a third with a combination of salicylic acid and lactic acid, and a fourth with imiquimod. Patients needing, respectively, one, two, or three visits for treatment of their mollusca were: 80.6%, 16.1%, and 3.2% for curettage, 36.7%, 43.3%, and 20.0% for cantharidin, 53.6%, 46.4%, and 0% for salicylic acid and glycolic acid, and 55.2%, 41.4%, and 3.4% for imiquimod. The rate of side effects was 4.7% for group 1, 18.6% for group 2, 53.5% for group 3, and 23.3% for group 4. Curettage was found to be the most efficacious treatment and had the lowest rate of side effects. It must be performed with adequate anesthesia and is a time-consuming procedure. Cantharidin is a useful bloodless alternative particularly in the office setting, but has moderate complications due to blisters and necessitated more visits in our experience. The topical keratolytic used was too irritating for children. Topical imiquimod holds promise but the optimum treatment schedule has yet to be determined. Finally, we believe that the ideal treatment for mollusca depends on the individual patient preference, fear, and financial status, distance from the office, and whether they have dermatitis or blood-borne infections.
authors.affiliation: CHU Sherbrooke, University of Montreal, Montreal, Quebec, Canada.
authors.forename: Dominique
authors.initials: D
authors.lastname: Hanna
authors.forename: Afshin
authors.initials: A
authors.lastname: Hatami
authors.forename: Julie
authors.initials: J
authors.lastname: Powell
authors.forename: Danielle
authors.initials: D
authors.lastname: Marcoux
authors.forename: Catherine
authors.initials: C
authors.lastname: Maari
authors.forename: Pascal
authors.initials: P
authors.lastname: Savard
authors.forename: Huguette
authors.initials: H
authors.lastname: Thibeault
authors.forename: Catherine
authors.initials: C
authors.lastname: McCuaig
mesh_terms: D000293:Adolescent; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003475:Curettage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008976:Molluscum Contagiosum / Q000188:drug therapy* / Q000453:epidemiology / Q000601:surgery; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents